You can edit almost every page by Creating an account. Otherwise, see the FAQ.

ObsEva SA

From EverybodyWiki Bios & Wiki

ObsEva SA
Founded 📆2012; 12 years ago (2012)
Founder 👔
Headquarters 🏙️Geneva, Switzerland
Area served 🗺️
Key people
  • Frank Verwiel
    (Chairman of the Board))
  • Ernest Loumaye
    (Chief Executive Officer)
  • Jean-Pierre Gotteland
    (Chief Scientific Officer)
  • Tim Adams
    (Chief Financial Officer)
    Wim Souverijns
    (Chief Commercial Officer)
Products 📟 
  • Nolasiban
Number of employees
47 (2019)
📇 Address
📞 telephone

ObsEva SA is a Swiss biopharmaceutical company specializing in the development and commercialization of novel therapeutics for women’s reproductive health and pregnancy.[1]


Co-founded in 2012 by Dr. Ernest Loumaye, the company’s name is a portmanteau of its specialization, ‘Obstetrics’, and the location of its headquarters, ‘Geneva’.

In January 2017, the company raised $97M[2] by completing an Initial Public Offering on the NASDAQ (symbol: OBSV) and established a U.S.-based office in Boston, Massachusetts.

In July 2018, ObsEva was listed on the SIX Exchange in Zurich, Switzerland (symbol: OBSN).[3]

As of 2019, the company had 47 employees, and this is expected to grow to support the build-out of a commercial organization.

Product pipeline[edit]

ObsEva has an established late-stage clinical pipeline and development program that focuses on in vitro fertilization (IVF), endometriosis, uterine fibroids, and preterm labor.[4] The company currently holds licenses for the development and commercialization of three products:

  • Nolasiban is an oral oxytocin receptor antagonist, a first-in-class compound for the improvement of IVF outcomes, which is in late stage clinical trials.
  • Linzagolix (OBE-2109/KLH-2109) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the treatment of endometriosis-associated pelvic pain, as well as heavy menstrual bleeding due to uterine fibroids, and is in late-stage clinical trials for both indications.
  • OBE022 is a selective, oral prostaglandin F2α receptor antagonist used for the treatment of acute preterm labor (PTL), and is in Phase 2 clinical development.

ObsEva licensed Nolasiban and OBE022 from Merck Serono at the inception of the company and holds worldwide rights.[5] Linzagolix was licensed from Kissei Pharmaceuticals in 2015 with worldwide rights excluding some Asian countries such as Japan.[6]


  1. Constable, Simon. "ObsEva: A Small Biotech With a Promising Pipeline". Retrieved 2019-06-08.
  2. "OBSEVA SA (OBSV) IPO". Retrieved 2019-06-08.
  3. GmbH, finanzen net. "ObsEva SA Shares to Begin Trading on SIX Swiss Exchange | Markets Insider". Retrieved 2019-06-08.
  4. "OBSN:SIX Swiss Ex Stock Quote - ObsEva SA". Retrieved 2019-06-08.
  5. "ObsEva gets funding and makes deal with Merck Serono". Retrieved 2019-06-08.
  6. Moore, Charles (2015-12-02). "ObsEva and Kissei Pharmaceutical Collaborate To Develop and Commercialize Endometriosis Drug KLH-2109". Endometriosis News. Retrieved 2019-06-08.

External links[edit]

This article "ObsEva SA" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ObsEva SA. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.